aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating [Seeking Alpha]
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.